Abstract: The present disclosure provides a Bifidobacterium lactis (B. lactis) strain XLTG11 and a use thereof. The strain belongs to Bifidobacterium lactis. The B. lactis strain XLTG11 was deposited in the China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2019, with a taxonomic name of Bifidobacterium lactis XLTG11 and an accession number of CGMCC No. 18738. The B. lactis strain XLTG11 provided by the present disclosure can regulate an inflammatory cytokine, improve an intestinal barrier function, and modulate an intestinal flora by inhibiting the activation of a TLR4/MYD88/NF-?B signaling pathway, thereby alleviating dextran sulfate sodium (DSS)-induced colitis. In addition, the B. lactis strain XLTG11 has an immune-enhancing effect on a cyclophosphamide (CTX)-induced mouse immunosuppression model.

Abstract: The presently disclosed subject matter relates to isolated compositions and methods for treating and/or preventing sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). In some embodiments, the presently disclosed subject matter relates to endothelial progenitor cell-derived exosomes to treat and/or prevent sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). The endothelial progenitor cell-derived exosomes can be modified to overexpress one or more miRNAs.

Abstract: Compositions comprising extracellular matrix (ECM) materials and methods of use thereof are disclosed. The compositions may comprise two or more ECM materials derived from different types of tissues, such as, e.g., lung tissue and spleen tissue, formulated for administration to a patient or configured as a medical device for implantation in or application to the patient. The compositions may combine complementary properties of different types of ECM materials for customized patient-specific and/or site-specific tissue repair and/or regeneration.

Abstract: The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.

Abstract: Provided are a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31 and CD200 and negative for CD45; a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31, CD157 and CD200 and negative for CD45; a mammalian vascular endothelial stem cell that is positive for the cell surface marker CD31, positive for at least one of CD157 and CD200, and negative for CD45; and a medicament for vascular regeneration, comprising any of the cell populations or the vascular endothelial stem cells as an active ingredient.

Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.

Abstract: The present invention provides a novel daptomycin-producing Streptomyces strain and use thereof, the strain is a subspecies of streptomyces griseus, named Streptomyces griseus L340, and the preservation number is CGMCC17921. The genetic character and fermentation unit of the strain provided by the present invention are relatively stable, the culture and fermentation conditions are suitable for industrial production of daptomycin, and the interference of pigment in later separation and purification is eliminated. The secondary metabolite daptomycin is obtained through fermentation of the Streptomyces provided by the present invention, which has the advantages of no interference of pigment accumulation, cleaner metabolic spectrum and thus is obviously superior in later separation and purification.

Abstract: The present invention relates to a method of reducing total gas production and/or methane production in a ruminant animal.

Abstract: Methods for improving quality of life and/or increasing activity in an aging and/or chronically ill mammal via administration of a composition of egg powder protein are provided.

Abstract: The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level.

Abstract: The disclosure relates to isolated microorganisms-including novel strains of the microorganisms-microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial ensembles, and compositions comprising the same, in methods for modulating the production of poultry, disease resistance, and egg yield. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of preventing colonization of pathogenic microbes.

Abstract: An analyte biosensor is provided having an analyte biosensing layer and an ethylene oxide absorption layer. The ethylene oxide absorption layer is provided over the analyte biosensing layer. A method is also provided.

Abstract: Provided is a composition comprising a novel strain, a lysate thereof or a culture product thereof, which can demonstrate excellent effects in strengthening skin barrier, moisturizing skin, enhancing skin elasticity or anti-aging, and can be used for a cosmetic composition or health functional food.

Abstract: A biocontrol strain YW-1, a preparation method and application of a biocontrol agent thereof are provided. The strain is Myroides odoratimimus with the preservation number of CGMCC NO. 20620. The biocontrol agent of the biocontrol strain YW-1 is obtained by the following steps: oscillating culture the biocontrol strain YW-1 in a LB culture medium at 30 Celsius degrees and 180 rpm for 12-16 hours until a total concentration of living bacteria in a bacterial suspension is 1×109-1×1010 CFU/mL; centrifuging the bacterial suspension at 6000 rpm for 10 minutes to collect bacterial cells; and diluting the bacterial cells with sterilized water to obtain a concentration of 100 CFU/milliliter. By irrigating the root of every plant with 20 milliliters of the biocontrol agent when host plants are transplanted, it can effectively prevent soil-borne diseases such as fusarium wilt of melons, bacterial wilt of tomatoes and peppers, and Phytophthora capsici.

Abstract: There is disclosed a cardiac explant-derived stem cell (EDC), the cell comprising a gene encoding an intermediate-conductance Ca2+-activated K+ channel, and wherein the gene causes an overexpression of the intermediate-conductance Ca2+-activated K+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs; introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.

Abstract: Methods and systems for isolating a high purity starch stream are provided. The methods provide an initial treatment step in advance of traditional grinding or fractionation operations (such as dry milling or wet milling operations) that facilitate separation of starch from other components of starch-based grains, for example facilitate separation of soft endosperm from other components of corn kernels including hard endosperm. The systems include a first treatment system for separating a high purity starch stream from other components of the grain stream, wherein the system can be configured as a bolt on for traditional milling operations such as wet milling and dry milling operations.

Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.

Abstract: Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided. The present invention also envisions kits comprising the expanded and unselected cord blood fractions.

Abstract: A method comprises printing a conductive ink on a substrate to form one or more electrodes and printing an electrode ink on one or more of the electrodes. The conductive and electrode inks are cured. Next, an enzyme ink layer is printed on at least one electrode, and the enzyme ink layer is cured with ultraviolet light. Each of the printing and curing processes are performed in an in-line process.

Abstract: The present invention features general-purpose microbiological growth media capable of supporting growth of microorganisms on membranes. The media contain casein digest, soybean digest, animal tissue digest, yeast extract, dextrose, a phosphate buffer, hemin, and L-cystine. The invention features an all-purpose microbiological growth media that can support the growth of anaerobes, molds, injured spores, and general aerobic bacteria to a greater extent than other media.